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Abstract
Background: Artemisinin combination therapies (ACTs) with broad efficacy are needed where multiple Plasmodium species are
transmitted, especially in children, who bear the brunt of infection in endemic areas. In Papua New Guinea (PNG), artemether-
lumefantrine is the first-line treatment for uncomplicated malaria, but it has limited efficacy against P. vivax. Artemisinin-
naphthoquine should have greater activity in vivax malaria because the elimination of naphthoquine is slower than that of
lumefantrine. In this study, the efficacy, tolerability, and safety of these ACTs were assessed in PNG children aged 0.5–5 y.
Methods and Findings: An open-label, randomized, parallel-group trial of artemether-lumefantrine (six doses over 3 d) and
artemisinin-naphthoquine (three daily doses) was conducted between 28 March 2011 and 22 April 2013. Parasitologic
outcomes were assessed without knowledge of treatment allocation. Primary endpoints were the 42-d P. falciparum PCR-
corrected adequate clinical and parasitologic response (ACPR) and the P. vivax PCR-uncorrected 42-d ACPR. Non-inferiority and
superiority designs were used for falciparum and vivax malaria, respectively. Because the artemisinin-naphthoquine regimen
involved three doses rather than the manufacturer-specified single dose, the first 188 children underwent detailed safety
monitoring. Of 2,542 febrile children screened, 267 were randomized, and 186 with falciparum and 47 with vivax malaria
completed the 42-d follow-up. Both ACTs were safe and well tolerated. P. falciparum ACPRs were 97.8% and 100.0% in
artemether-lumefantrine and artemisinin-naphthoquine-treated patients, respectively (difference 2.2% [95% CI 23.0% to
8.4%] versus 25.0% non-inferiority margin, p= 0.24), and P. vivax ACPRs were 30.0% and 100.0%, respectively (difference
70.0% [95% CI 40.9%–87.2%], p,0.001). Limitations included the exclusion of 11% of randomized patients with sub-threshold
parasitemias on confirmatory microscopy and direct observation of only morning artemether-lumefantrine dosing.
Conclusions: Artemisinin-naphthoquine is non-inferior to artemether-lumefantrine in PNG childrenwith falciparummalaria but has
greater efficacy against vivax malaria, findings with implications in similar geo-epidemiologic settings within and beyond Oceania.
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Introduction
Malaria control programs incorporating artemisinin combina-
tion therapy (ACT) have contributed to a decline in malaria
morbidity and mortality worldwide, renewing interest in global
eradication [1]. However, in geo-epidemiologic settings outside
sub-Saharan Africa where there is transmission of multiple
Plasmodium species, P. vivax remains a major obstacle to
eradication because of its complex life cycle and transmission
biology [2]. There is the potential for late relapses from liver-stage
hypnozoites, but also growing evidence that the burden of disease
and the potential for death from acute P. vivax infections have
both been underestimated [3,4].
Transmission of both P. falciparum and P. vivax can
complicate the choice of antimalarial treatment. A recent trial of
ACTs involving children from Papua New Guinea (PNG) with
uncomplicated malaria showed that the most efficacious were
artemether-lumefantrine for P. falciparum and dihydroartemisi-
nin-piperaquine for P. vivax infections [5]. Because of the
impracticality of species-specific treatment where there are limited
diagnostic facilities, and because falciparum malaria more often
progresses to complications and death, artemether-lumefantrine
was chosen as the first-line therapy under 2009 PNG national
guidelines [6]. This recommendation means that potentially
preventable morbidity and mortality due to vivax malaria remain
of concern [7].
There is a need for assessment of other ACTs that might
replicate the high cure rate of artemether-lumefantrine in
falciparum malaria while ensuring that vivax malaria is also
effectively treated in PNG and similar epidemiologic settings. Of
the few available alternatives, artemisinin-naphthoquine has been
marketed in a range of countries in Africa, Asia, and Oceania as
single-dose treatment based on limited pharmacologic, efficacy,
and safety data in adults [8,9] and without World Health
Organization (WHO) prequalification. Because of its commercial
availability in PNG, and as a prelude to a formal safety and
efficacy comparison with artemether-lumefantrine, we performed
pharmacokinetic dose-finding studies in PNG children aged 5–10
y, which provided evidence that a 3-d daily artemisinin-
naphthoquine regimen was well tolerated, safe, and efficacious
for uncomplicated malaria [10,11]. This regimen satisfies the
WHO requirement that ACTs be administered over 3 d to retard
parasite drug resistance and improve efficacy [12]. In addition, the
elimination half-life of naphthoquine [10] is longer than that of
piperaquine [13], suggesting that it should be more effective in
suppressing P. vivax relapses in patients treated for vivax or
falciparum malaria [5].
The aim of the present study was to compare the efficacy of
three daily artemisinin-naphthoquine doses to that of a six-dose, 3-
d artemether-lumefantrine regimen in PNG children aged 0.5–5 y
with uncomplicated malaria. We hypothesized that artemisinin-
naphthoquine would be well tolerated and safe in this younger
vulnerable pediatric population, and that its efficacy would be (i)
non-inferior to that of artemether-lumefantrine for falciparum
malaria and (ii) superior to that of artemether-lumefantrine for
vivax malaria.
Methods
Study Design, Setting, and Approvals
This open-label, parallel-group trial was conducted at the Mugil
and Alexishafen Health Centers, Madang Province, PNG, from 28
March 2011 to 22 April 2013. The primary efficacy endpoints
were (i) reappearance of P. falciparum within 42 d of treatment
after correction for reinfections identified by polymerase chain
reaction (PCR) genotyping of polymorphic parasite loci, and (ii)
appearance of any P. vivax parasitemia within 42 d after
treatment for vivax malaria. Secondary endpoints for falciparum
malaria, assessed over 42 d, were (i) reappearance of PCR-
uncorrected P. falciparum parasitemia, (ii) appearance of P. vivax
parasitemia, and (iii) persistence/appearance of P. falciparum
gametocytes. For vivax malaria, secondary endpoints were (i)
persistence/appearance of P. vivax gametocytes over 42 d and (ii)
reappearance of PCR-corrected P. vivax over 42 d (added post
hoc when genotyping techniques became available [14]). Although
the WHO recommendation is 28 d of post-treatment monitoring
[15], monitoring can be extended to 42 d in the case of ACT
partner drugs with a long half-life [12]. Analyses of key outcomes
were thus performed at both 28 d and 42 d. Safety assessment
included conventional clinical and laboratory monitoring as well
as electrocardiographic indices.
Since artemether-lumefantrine has a high (.95%) day-42
adequate parasitologic and clinical response (ACPR) for falci-
parum malaria in the PNG pediatric population [5], a non-
inferiority study design was selected. A sample size of 220 per
falciparum malaria treatment arm was chosen based on the
assumption that the P. falciparum day-42 PCR-corrected ACPR
for artemether-lumefantrine would be 95.2% (as in our previous
study [5]), a 5% non-inferiority margin for artemisinin-naphtho-
quine or artesunate-pyronaridine (approximating the 10% failure
rate recommended by WHO for change in treatment policy [12]),
25% attrition, 5% type 1 error (one-tailed), and 80% power. For
vivax malaria, given that artemether-lumefantrine has a low cure
rate and that dihydroartemisinin-piperaquine was twice as
efficacious as artemether-lumefantrine in PNG children in our
previous study [5], a superiority study design was used. A sample
size of 60 children per arm was selected under the assumption that
the day-42 uncorrected P. vivax ACPR for artemisinin-naphtho-
quine or artesunate-pyronaridine would be superior (at least
double the 30.3% ACPR for artemether-lumefantrine [5]), with
25% attrition, 5% type 1 error (two-tailed), and 90% power.
The original study design involved a comparison of conven-
tional artemether-lumefantrine with both artemisinin-naphtho-
quine and artesunate-pyronaridine. Artesunate-pyronaridine was
not initially available because concerns regarding hepatotoxicity
were being addressed [16]. The subsequent recommendation that
this ACT be limited to a single lifetime dose made its use
untenable for malaria treatment programs in countries such as
PNG where children are at risk of repeated episodes of malaria
[17], and, as a result, the trial was conducted as a two-arm
comparison. A prespecified artemisinin-naphthoquine safety
assessment was scheduled after 50 patients, as well as further
interim efficacy analyses and safety assessments that were
scheduled primarily to determine whether artemisinin-naphtho-
quine violated the non-inferiority margin in the case of falciparum
malaria or unexpected toxicity had emerged.
The study was approved by the PNG Institute of Medical
Research Review Board, the Medical Research Advisory Com-
mittee of PNG, and the University of Western Australia Human
Research Ethics Committee. Written informed consent was
obtained from parents/guardians of all children.
Patients
Children aged 0.5–5 y presenting with an axillary temperature
.37.5uC or a history of fever during the previous 24 h were
screened using on-site blood film microscopy. Those with P.
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falciparum (.1,000 asexual parasites/ml whole blood) or P. vivax
(.250/ml) were eligible if (i) there were no features of severity [18],
(ii) they had not taken a study drug in the previous 14 d, (iii) there
was no history of allergy to study drugs, and (iv) there was no
evidence of another infection or co-morbidity.
Clinical Procedures
An initial standardized clinical assessment was performed, and
blood was drawn for measurement of hemoglobin and blood
glucose (Hemocue 201+, Hemocue, A¨ngelholm, Sweden), as well as
hepatic and renal function (Vitros DT60 II system, Ortho Clinical
Diagnostics, Mulgrave, Victoria, Australia) and a full blood count
(Coulter Ac?T diff, Beckman Coulter, Brea, California, US). A 12-
lead electrocardiograph was taken for measurement of the QT





) to allow comparisons
with other studies in the PNG pediatric population involving
antimalarial drugs with effects on ventricular repolarization in
which this correction has been applied [11,19,20].
Based on computer-generated block randomization (24 children
per site), eligible patients were allocated 1:1 to artemether-
lumefantrine (1.7 mg/kg artemether plus 10 mg/kg lumefantrine;
Novartis Pharma, Basel, Switzerland) twice daily for 3 d or to
artemisinin-naphthoquine (20 mg/kg artemisinin plus 8 mg/kg
naphthoquine; Kunming Pharmaceutical Corporation, Yunnan,
China) daily for 3 d. Randomization was independent of
Plasmodium species. Allocated treatments were concealed in
sealed numbered envelopes that were opened in sequence by
study medical or nursing staff, and the specified treatment was
administered. As recommended by the respective manufacturers,
artemether-lumefantrine was administered as 1–3 whole tablets
per dose with 250 ml of milk to optimize bioavailability [21], and
artemisinin-naphthoquine as 1–4 whole tablets per dose with
water.
Treatments were not blinded, primarily because the endpoints
were based on objective clinical and parasitologic criteria. In
addition, we sought to simplify drug administration as much as
possible to maximize patient adherence and retention, including
only once daily dosing and the avoidance of potential gastroin-
testinal side effects with the unnecessary ingestion of milk in
children allocated artemisinin-naphthoquine [10]. Only the
evening artemether-lumefantrine dose was unsupervised, being
administered at home by parents/guardians who were instructed
as to the importance of dosing with milk, which was supplied for
this purpose. Adherence was verified by study staff the following
morning in each case, and a day-7 plasma lumefantrine
concentration was determined for each child. Children vomiting
within 30 min of drug administration were to be retreated.
Standardized assessment, including axillary temperature and
blood film microscopy, was repeated on days 1, 2, 3, 7, 14, 28, and
42. Blood was drawn for full blood count and hepatorenal
function, and an electrocardiograph was taken, on days 0, 3, and
7. An additional electrocardiograph was performed 4 h after the
day-2 dose (at the predicted peak plasma naphthoquine concen-
tration [10]) in artemisinin-naphthoquine-treated children and in
a convenience sample of 30 children at the same time after the
morning dose of artemether-lumefantrine. All blood films were
reexamined independently by two skilled microscopists who were
blind to allocated treatment. Parasite density was calculated from
the number of parasites per 200–500 leucocytes and an assumed
leucocyte count of 8,000/ml. Slides discrepant for positivity/
negativity, speciation, or density (.36difference) were adjudicat-
ed by a senior microscopist.
Efficacy was assessed using WHO definitions [15]. Early
treatment failure (ETF) was defined as the development of signs
of severity or an inadequate parasitologic response by day 3. Any
child developing parasitemia between days 4 and 42 was
considered a late parasitologic failure (LPF) or, if febrile, late
clinical failure (LCF). An ACPR was recorded otherwise. P.
falciparum reinfection and recrudescence were distinguished using
PCR genotyping of merozoite surface protein 2 (MSP2) and MSP1
based on paired samples collected on day 0 and at reappearance
[22,23]. P. vivax recrudescence was determined based on
genotyping of MSP1F3 and Microsatellite 16 [14]. Parasite
clearance time (PCT) and fever clearance time (FCT) were
defined as the times to the first of two consecutive assessments at
which the child was afebrile and slide-negative, respectively.
Day-7 plasma lumefantrine concentrations were determined
using a validated ultra-high-performance liquid chromatography–
tandem mass spectrometry assay as previously described [24,25].
The inter-day and intra-day variability were #11.2% and #9.6%,
respectively, at concentrations over the linear range between 20
and 20,000 ng/ml.
Statistical Analysis
Per-protocol prespecified analyses included children with
complete follow-up or a confirmed treatment failure, and excluded
those treated for malaria without confirmatory microscopy, those
for whom the alternative Plasmodium species was detected, and
those who defaulted from follow-up despite repeated attempts at
contact. These excluded patients were retained in prespecified
modified intention-to-treat analyses utilizing (i) a worst-case
approach (ETF assumed for day-3 exclusions, LPF/LCF other-
wise) and (ii) a best-case approach (all missing follow-up blood
films assumed parasite-negative) [5].
Kaplan-Meier estimates were computed for each endpoint
defined by parasite species. Statistical analysis was performed
using IBM SPSS Statistics version 20 (IBM Corporation, Somers,
New York, US) and STATA/IC 11.2 (StataCorp, College Station,
Texas, US). Two-sample comparisons for normally distributed
variables were by Student’s t test, for non-normally distributed
variables by Mann-Whitney U test, and for proportions by Fisher’s
exact test. Safety and tolerability were assessed from the incidence
of symptoms/signs to day 7 using Poisson regression. Kaplan-
Meier estimates were computed for each endpoint by Plasmodium
species, and treatments compared by log-rank test. Differences in
parasitemia, gametocytemia, and hemoglobin concentration by
treatment type and time were assessed using generalized linear
modeling with Bonferroni correction to adjust for multiple
pairwise comparisons, and with adjustment for parasitemia in
the case of hemoglobin. Unless otherwise stated, all p-values are
two-tailed, with p,0.05 taken as significant.
Results
Trial Profile
The first patient was recruited on 28 March 2011, and the last
follow-up was completed on 22 April 2013. No adverse events
occurred in the first 50 patients. A further safety assessment was
scheduled when one-third of the total planned sample size of 560
had been recruited. Safety data were available for 91 artemether-
lumefantrine-treated and 97 artemisinin-naphthoquine-treated
children at that time (including those excluded post hoc; see
Figure 1). No significant drug-related adverse events had occurred.
Detailed safety monitoring was therefore stopped, but scheduled
visits still included basic clinical/laboratory parameters including
axillary temperature, blood film microscopy, and hemoglobin
Artemisinin-Naphthoquine for Pediatric Malaria
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concentration. A prespecified interim efficacy analysis was
performed when nearly 50% of the sample had been recruited
(267 of 560). This analysis showed that artemisinin-naphthoquine
was non-inferior for falciparum malaria and superior for vivax
malaria compared with artemether-lumefantrine (see below),
justifying cessation of the trial.
Of 267 randomized children, 36 (13.5%) were excluded post
hoc because of protocol violations (20 allocated to artemether-
lumefantrine and 16 to artemisinin-naphthoquine; see Figure 1).
Six children had not taken study treatment as stipulated (three
allocated to each treatment), seven were slide-negative by expert
microscopy (four allocated to artemether-lumefantrine and three
to artemisinin-naphthoquine), and 23 had sub-threshold parasite
densities by expert microscopy (13 allocated to artemether-
lumefantrine and ten to artemisinin-naphthoquine). There were
no significant differences between treatment allocations for the
proportions of total exclusions or individual reasons for exclusion
(p.0.47 in each case). In addition, there were no differences
between the treatments allocated to the 23 excluded patients who
had falciparum malaria or between the treatments allocated to the
six with vivax malaria (p.0.67). The 15 children (6.5% of the
randomized sample) presenting with mixed P. falciparum/P.
vivax infections at densities above each species-specific threshold
were included in both species arms [5]. A single patient with P.
malariae infection completed all study procedures but was not
included in analyses.
Of the remaining 230 children, the day-42 retention was $92%
for all species/treatment groups. Ten children (six allocated to
artemether-lumefantrine and four to artemisinin-naphthoquine, all
with falciparum malaria) withdrew during follow-up. None of these
children had experienced adverse effects; they had all relocated
outside the study catchment areas. Two children with P. falciparum
infections in the artemether-lumefantrine arm were found to have
symptomatic vivax malaria on day 28 with parasitemias of 21,137/
ml and 1,609/ml, respectively. These patients were retreated with
artemether-lumefantrine under national guidelines [6] at that time
and were excluded from the per-protocol analysis. The remaining
children with P. vivax detected during follow-up after treatment for
falciparum malaria were mostly asymptomatic and had lower
parasitemias, and were either not treated or given artemether-
lumefantrine on day 42 after assessment. One child with P. vivax at
recruitment who was allocated to artemisinin-naphthoquine
attended all follow-up visits but did not have parasitologic data at
day 28 and was excluded from the per-protocol analysis. All
children allocated artemether-lumefantrine had detectable lume-
fantrine in plasma on day 7, with a median concentration (192 ug/l
[interquartile range 122–352]) consistent with all six doses having
been administered successfully [24,25].
Figure 1. Trial profile showing numbers of patients remaining in the study from screening to day-42 assessment. PCR-corrected
denotes correction for reinfections identified by polymerase chain reaction genotyping of polymorphic parasite loci.
doi:10.1371/journal.pmed.1001773.g001
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Safety Assessment
There were no significant differences in baseline demographic
and anthropometric characteristics (age, sex, weight, height, and
mid-upper-arm circumference), vital signs (axillary temperature,
heart rate, and respiratory rate), hematologic parameters (white
and red blood cell counts, platelet count, and hemoglobin
concentration), or blood glucose concentrations between the 91
children allocated to artemether-lumefantrine and the 97 who
received artemisinin-naphthoquine in the detailed safety assess-
ment (p$0.21; see Table 1). No child in either group had a
baseline serum creatinine concentration more than three times the
upper limit of the reference range (ULRR) for PNG children [26]
($112 mmol/l), but two children in the artemether-lumefantrine
group had a baseline serum alanine aminotransferase (ALT)
concentration more than three times the ULRR ($130 U/l; see
Table 2). Consistent with malaria-associated hemolysis, approxi-
mately one-third of the children in both groups had a baseline
serum total bilirubin concentration more than three times the
ULRR ($24 mmol/l), but there was no between-group difference
in this proportion (p= 0.60) and no children were considered to
have jaundice.
Both treatments were well tolerated, and there were no
between-group differences in the incidence rates of reported/
observed signs and symptoms during the first 7 d of follow-up,
apart from a significantly greater incidence of abdominal pain in
the artemisinin-naphthoquine-treated patients (incidence rate
Table 1. Demographic, clinical, and laboratory parameters as part of safety monitoring.
Parameter Artemether-Lumefantrine Artemisinin-Naphthoquine p-Value
n Mean ± SD, Median (IQR), or Percentage n Mean ± SD, Median (IQR), or Percentage
Day 0
Age (months) 91 44.2614.2 97 42.764.6 0.50
Sex (percent male) 91 44.0% 97 49.5% 0.47
Body weight (kg) 90 12.762.1 95 12.762.5 0.87
Height (cm) 83 93.8610.3 91 92.9610.3 0.55
Mid-upper-arm circumference (cm) 90 15.0 (14.0–15.0) 94 14.5 (14.0–15.5) 0.39
Axillary temperature (uC) 90 38.061.3 95 38.161.4 0.74
Pulse rate (/min) 89 123620 92 126621 0.26
Respiratory rate (/min) 89 32 (28–37) 93 32 (26–38) 0.55
White blood cells (6 109/l) 85 6.9 (5.4–9.8) 91 7.4 (5.0–9.3) 0.78
Red blood cells (6 1012/l) 85 3.68 (3.03–4.27) 91 3.77 (3.23–4.34) 0.55
Platelets (6 109/l) 84 85 (64–132) 91 102 (63–137) 0.78
Hemoglobin (g/l) 89 93 (81–104) 94 91 (81–102) 0.31
Blood glucose (mmol/l) 83 6.4 (5.7–7.6) 87 6.7 (5.8–7.4) 0.59
Reticulocytes (percent) 48 1.2% (0.6%–2.9%) 48 0.8% (0.6%–2.0%) 0.21
Day 3
Axillary temperature (uC) 88 36.460.4 94 36.260.5 0.002
Pulse rate (/min) 87 107615 94 107617 0.36
Respiratory rate (/min) 88 28 (24–32) 94 28 (24–32) 0.95
White blood cells (6 109/l) 87 7.0 (5.5–8.7) 90 7.1 (5.9–8.5) 0.71
Red blood cells (6 1012/l) 87 3.47 (3.03–3.91) 90 3.57 (3.03–4.09) 0.65
Platelets (6 109/l) 87 142 (107–180) 90 149 (102–188) 0.63
Hemoglobin (g/l) 88 87 (75–96) 94 86 (73–99) 0.92
Blood glucose (mmol/l) 78 5.9 (5.3–6.5) 81 5.8 (5.3–6.6) 0.73
Reticulocytes (percent) 49 1.2% (0.6%–3.4%) 49 0.8% (0.5%–1.3%) 0.10
Day 7
Axillary temperature (uC) 89 36.560.6 92 36.660.6 0.51
Pulse rate (/min) 89 105618 94 106619 0.68
Respiratory rate (/min) 89 28 (24–31) 94 28 (24–32) 0.41
White blood cells (6 109/l) 87 8.1 (6.1–9.5) 88 8.4 (7.1–10.7) 0.01
Red blood cells (6 1012/l) 87 3.64 (3.34–4.25) 88 3.61 (3.15–4.19) 0.43
Platelets (6 109/l) 87 245 (191–337) 88 257 (187–315) 0.59
Hemoglobin (g/l) 87 93 (80–102) 94 91 (80–101) 0.64
Blood glucose (mmol/l) 80 5.9 (5.3–6.5) 82 6.1 (5.4–6.5) 0.70
Reticulocytes (percent) 49 3.6% (1.4%–6.2%) 49 2.3% (1.3%–3.6%) 0.05
IQR, interquartile range; SD, standard deviation.
doi:10.1371/journal.pmed.1001773.t001
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11.6% versus 7.8% in the artemether-lumefantrine group;
incidence rate ratio 1.48 [95% CI 1.03–2.13], p= 0.033). This
symptom was mild and short-lived in all cases (see Table 3). On
day 3, one child in each group had a serum ALT more than three
times the ULRR, but both were afebrile and asymptomatic, and
this abnormality had resolved in both cases by day 7 (see Table 2).
Most children had a normal serum bilirubin by day 7. No child
became hypoglycemic. Other statistically significant between-
group differences in vital signs and hematologic parameters on
days 3 and 7 were not clinically significant.
Despite the technical challenges associated with performing
electrocardiography in unwell children in a rural clinic, interpret-
able traces were obtained from between 68% and 88% of the
children in each group at each time point. The QTc increased
from baseline to 4 h after the last dose of artemisinin-naphtho-
quine by a median of 28 msec0.5 (interquartile range 18–36) (p,
0.01 versus artemether-lumefantrine-treated children; see Figure 2
and Table 4). Most values had returned to baseline by day 7, with
a prolongation relative to baseline of 5 msec0.5 (interquartile range
2–9). There were no significant changes in QTc in the artemether-
lumefantrine group. Twenty-six of 102 children (25.5%, all but
one in the much larger artemisinin-naphthoquine group) with an
interpretable electrocardiograph on day 2 had QTc.460 msec
0.5.
The longest QTc at this time point was 505 msec
0.5, in an
artemisinin-naphthoquine-treated child. No dysrhythmias, dys-
pnea, syncope, or other transient neurologic events were recorded
during follow-up.
The only severe adverse event was considered non-drug related.
A 48-mo-old child allocated to artemisinin-naphthoquine was
hospitalized with, and treated successfully for, lobar pneumonia
diagnosed on day 23 of follow-up. This patient was negative by
both microscopy and PCR for malaria at the time of re-
presentation.
Antimalarial Efficacy
The two falciparum malaria treatment groups were well
matched for age, sex, anthropometric measures, vital signs, and
other characteristics (see Table 5). Initial fever and parasite
clearance were prompt. Most children in each group ($88.0%)
were afebrile, and approximately one-third were parasite negative,
by day 1, and almost all had cleared their fever (100.0% in the
artemether-lumefantrine arm versus 98.0% in the artemisinin-
naphthoquine arm, p= 0.25) and parasitemia (99.0% versus
98.0%, p.0.99) by day 3 (see Table 6).
The PCR-corrected P. falciparum ACPR was 98.9% (95% CI
94.3%–100%; 93 of 94 children) and 100% (95% CI 95.2%–
100%; 96 of 96 children) in the artemether-lumefantrine and
artemisinin-naphthoquine groups, respectively, on day 28 (a
secondary endpoint), and 97.8% (95% CI 91.6%–99.6%; 90 of
92 children) and 100% (95% CI 95.1%–100%; 94 of 94 children),
respectively, on day 42 (a primary endpoint, p= 0.15 by log-rank
test; see Figure 3 and Table 7). Using these latter data and the
same 5.0% non-inferiority margin, type 1 error probability, and
power as in the original sample size estimates, the 186 children
who completed follow-up exceeded the total of 52 required to
show non-inferiority of artemisinin-naphthoquine for this primary
endpoint [27]. In addition, the non-inferiority margin of 25.0%
fell below the confidence interval for the difference between
Table 2. Biochemical measurements in the safety sub-study by allocated treatment.
Measurement Artemether-Lumefantrine Artemisinin-Naphthoquine p-Value
Day 0 (baseline)
Serum creatinine (mmol/l) 38 (29–47) (n= 72, 79%) 23 (28–43) (n= 73, 75%) 0.09
Elevated creatinine*, n (percent) 0 (0%) 0 (0%) .0.99
Serum ALT (U/l) 20 (13–35) (n= 72, 79%) 20 (13–28) (n= 67, 69%) 0.86
Elevated ALT*, n (percent) 2 (2.8%) 0 (0%) 0.50
Serum total bilirubin (mmol/l) 20 (12–25) (n= 74, 81%) 21 (12–26) (n= 75, 77%) 0.77
Elevated bilirubin*, n (percent) 22 (29.7%) 26 (34.7%) 0.60
Day 3
Serum creatinine (mmol/l) 36 (27–41) (n= 74, 81%) 37 (31–44) (n= 73, 75%) 0.23
Elevated creatinine*, n (percent) 0 (0%) 0 (0%) .0.99
Serum ALT (U/l) 18 (16–20) (n= 73, 80%) 20 (17–26) (n= 67, 69%) 0.16
Elevated ALT*, n (percent) 1 (1.4%) 1 (1.5%) .0.99
Serum total bilirubin (mmol/l) 14 (6–17) (n= 70, 77%) 13 (6–17) (n= 67, 69%) 0.94
Elevated bilirubin*, n (percent) 2 (2.9%) 1 (1.5%) .0.99
Day 7
Serum creatinine (mmol/l) 29 (22–34) (n= 71, 78%) 28 (24–40) (n= 71, 73%) 0.43
Elevated creatinine*, n (percent) 0 (0%) 0 (0%) .0.99
Serum ALT (U/l) 18 (12–25) (n= 70, 77%) 21 (16–29) (n= 67, 69%) 0.03
Elevated ALT*, n (percent) 0 (0%) 0 (0%) .0.99
Serum total bilirubin (mmol/l) 11 (8–16) (n= 71, 78%) 14 (9–15) (n= 69, 71%) 0.63
Elevated bilirubin*, n (percent) 2 (2.8%) 5 (7.2%) 0.27
Data are median (interquartile range) or n (percent).
*Elevated serum creatinine ($112 mmol/l), serum ALT ($130 U/l), and total serum bilirubin ($23.8 mmol/l) are defined as.3 times the upper limit of normal values in
PNG children aged ,5 y [26].
doi:10.1371/journal.pmed.1001773.t002
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treatments (2.2% [95% CI 23.0% to 8.4%]), further evidence of
non-inferiority.
The prespecified secondary endpoint of day-42 uncorrected
ACPR was significantly greater in the artemisinin-naphthoquine
group (100% [95% CI 95.1%–100%] versus 94.6% [95% CI
87.2%–98.0%] in the artemether-lumefantrine-treated children,
p= 0.028; see Table 8). In addition, the appearance of P. vivax
after treatment for P. falciparum, also a secondary endpoint, was
significantly less frequent in the artemisinin-naphthoquine group
(0% versus 34.0% in in the artemether-lumefantrine-treated
children, p,0.001; see Table 7). The modified intention-to-treat
analyses showed results that were consistent with these findings
(see Tables 9 and 10).
The two vivax malaria treatment groups were also well matched
for baseline characteristics (see Table 5). Parasite clearance was
more rapid in children with vivax malaria than in the children
with falciparum malaria, with .84% of children with vivax
malaria in both treatment groups slide-negative for asexual forms
of P. vivax by day 1, and 100.0% in both treatment groups both
afebrile and aparasitemic by day 3 (see Table 6).
The day-42 PCR-uncorrected ACPR for P. vivax infections was
30.0% (95% CI 12.8%–54.2%; six of 20 children) in the
artemether-lumefantrine group and 100% (95% CI 84.5%–
100%; 26 of 26 children) in the artemisinin-naphthoquine group
(see Figure 3 and Table 7). Using these data and the same type 1
error probability and power as in the original sample size
estimates, the 46 children who completed the trial exceeded the
total of ten children required to show superiority of artemisinin-
naphthoquine for this primary endpoint [28]. The significantly
greater day-42 ACPR for artemisinin-naphthoquine remained
after PCR correction of post-treatment responses for infections
with different genetic profiles than those at baseline (100% [95%
CI 84.0%–100%] versus 60.0% [95% CI 36.4%–80.0%] in the
artemether-lumefantrine-treated children, p,0.001; see Table 8).
The modified intention-to-treat analyses showed results that were
consistent with these findings (see Tables 9 and 10).
The single patient with P. malariae infection was randomized to
artemether-lumefantrine and responded with prompt parasite
clearance and an ACPR at days 28 and 42.
Gametocyte Carriage and Hemoglobin Concentration
The percentage of children carrying P. falciparum gametocytes
based on microscopy was not significantly different between groups
at baseline (p= 0.36), but artemisinin-naphthoquine-treated patients
were more likely to have gametocytemia between days 3 and 14 (see
Figure 4). The odds ratio for carriage in the artemisinin-naphtho-
quine group was 3.2 (95% CI 1.5–6.8) that of children in the
artemether-lumefantrine group on day 7, and 15.1 (95% CI 1.9–
118.1) on day 14. When only those children who were gametocyte
positive at baseline were considered (n= 32 in the artemether-
lumefantrine group and n= 39 in the artemisinin-naphthoquine
group), the equivalent odds ratios for gametocyte carriage on days 7
and 14 were 2.6 (95% CI 1.0–6.8) and 10.7 (95% CI 1.3–88.8).
In patients with vivax malaria, there was prompt gametocyte
clearance in both groups by day 4, but, consistent with more
frequent treatment failure in the artemether-lumefantrine group, a
significant proportion of patients (40.0%) had become positive for
gametocytes by day 42, while none of the artemisinin-naphtho-
quine-treated children were gametocytemic at that time (see
Figure 4).
Table 3. Incidence rate of main reported or observed signs and symptoms during the first 7 d of follow-up in randomized
children, expressed as reports per 100 observations.
Sign/Symptom Incident Rate (95% CI) IRR (95% CI) p-Value
Artemether-Lumefantrine (n=130) Artemisinin-Naphthoquine (n=127)
Fever 27.9 (24.4–31.5) 30.7 (27.1–34.5) 1.10 (0.90–1.35) 0.37
Chills 5.8 (4.1–7.9) 6.3 (4.5–8.5) 1.08 (0.69–1.70) 0.72
Headaches 7.5 (5.6–9.8) 10.1 (7.9–12.8) 1.35 (0.93–1.97) 0.12
Child irritable/frequent crying 2.7 (1.6–4.2) 3.4 (2.1–5.11) 1.27 (0.67–2.41) 0.46
Trouble sleeping 0.9 (0.4–2.0) 1.3 (0.6–2.5) 1.37 (0.48–3.95) 0.56
Problems eating/breast feeding 12.4 (10.0–15.2) 11.7 (9.3–14.5) 0.94 (0.68–1.29) 0.70
Vomiting 4.2 (2.8–6.1) 5.8 (4.1–7.9) 1.37 (0.83–2.26) 0.21
Diarrhea 4.9 (3.3–6.8) 3.5 (3.2–5.3) 0.73 (0.42–1.26) 0.26
Abdominal pain 7.8 (5.8–10.1) 11.6 (9.2–14.3) 1.48 (1.03–2.13) 0.03
Cough 24.0 (20.8–27.5) 29.1 (25.6–32.8) 1.21 (0.98–1.50) 0.08
Difficulty breathing 0.9 (0.3–2.0) 0.3 (0.0–1.2) 0.34 (0.07–1.70) 0.19
Rhinorrhea 23.9 (20.6–27.4) 22.1 (18.9–25.6) 0.93 (0.74–1.17) 0.53
Skin rash (reported) 3.3 (2.0–5.0) 3.1 (1.9–4.7) 0.93 (0.50–1.73) 0.82
Skin rash (observed) 0.3 (0.0–1.1) 1.1 (0.5–2.3) 3.60 (0.75–17.33) 0.11
Skin lesion 2.7 (1.6–4.2) 2.4 (1.4–4.0) 0.91 (0.45–1.82) 0.79
Pallor 6.7 (4.9–8.9) 9.3 (7.2–11.9) 1.39 (0.94–2.06) 0.10
Crackles at lung bases 3.0 (1.8–4.6) 1.6 (0.8–2.9) 0.54 (0.25–1.16) 0.12
Presence of enlarged spleen 22.9 (19.7–26.4) 26.5 (23.1–30.2) 1.16 (0.92–1.44) 0.20
Poisson regression with follow-up time as the exposure was used to derive incident rate ratios with artemether-lumefantrine as reference. Data on signs/symptoms from
ten children were lost prior to database entry.
IRR, incident rate ratio.
doi:10.1371/journal.pmed.1001773.t003
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Hemoglobin concentrations in children treated for falciparum
malaria were similar in the two treatment groups until day 42 after
treatment, when the artemisinin-naphthoquine-treated children
had a significantly higher mean concentration (109613 g/l versus
102612 g/l in the artemether-lumefantrine group, p,0.001; see
Figure 5). In patients with vivax malaria, the hemoglobin
concentrations had diverged significantly at day 7, but this
difference was not sustained.
Discussion
Three daily doses of artemisinin-naphthoquine proved a highly
efficacious treatment for both falciparum and vivax malaria in PNG
children living in an area of intense transmission of multiple
Plasmodium species. This efficacy profile addresses recognized
species-specific shortcomings associated with artemether-lumefan-
trine and dihydroartemisinin-piperaquine in this patient group [5].
Artemisinin-naphthoquine was well tolerated, and there were no
significant safety concerns identified through detailed post-treatment
monitoring. Artemisinin-naphthoquine treatment was associated
with a higher day-42 hemoglobin concentration than artemether-
lumefantrine treatment, with potential implications for attenuated
morbidity associated with subsequent malarial episodes and other
illnesses. A further advantage of artemisinin-naphthoquine is that it is
taken once daily and without the need for co-administration with fat
[10], which should improve adherence compared with the relatively
complex six-dose artemether-lumefantrine schedule with milk co-
administration. Artemisinin-naphthoquine was, however, associated
with greater post-treatment gametocyte carriage and, as is the case
for a number of other ACT partner drugs, with prolongation of the
QTc interval.
There were no reappearances of asexual forms of either P.
falciparum or P. vivax during 42 d of follow-up in any child
treated with three daily doses of artemisinin-naphthoquine in the
present study. Treatment failures were observed in our previous
single- and two-dose studies in PNG children aged 5–10 y [11],
and most studies in adults utilizing similar regimens have fallen
short of a 100% ACPR, even with only 28 d of follow-up
[8,9,29,30], including an Indonesian study with a 28-d ACPR of
79% in mixed P. falciparum/P. vivax infections [8,9]. Only one
other study, in Chinese adults with vivax malaria, has utilized a 3-
d artemisinin-naphthoquine regimen (17.5 mg/kg artemisinin plus
7 mg/kg naphthoquine versus 20 mg/kg artemisinin plus 8 mg/
kg artemisinin in the present study), and this regimen was
associated with a day-42 ACPR of 98.4% [31]. Overall, these data
support a 3-d regimen to maximize the efficacy of artemisinin-
naphthoquine. The present artemisinin-naphthoquine outcomes
are clearly superior to the outcomes of both artemether-
lumefantrine and dihydroartemisinin-piperaquine in our previous
multi-arm trial in young PNG children, since these regimens were
associated with P. falciparum day-42 PCR-corrected ACPRs of
95.2% and 87.9%, respectively, and P. vivax day-42 uncorrected
ACPRs of 30.3% and 69.4%, respectively [5].
We hypothesize that the better efficacy of artemisinin-
naphthoquine reflects naphthoquine’s relatively long terminal
elimination half-life and wide therapeutic index. The mean
elimination half-life of naphthoquine in PNG children is 21–
25 d [10] compared with 14–21 d for piperaquine in this patient
group [32–34]. This indicates that naphthoquine can suppress
reappearances of both P. falciparum and P. vivax for a longer
period than piperaquine and especially lumefantrine, which has an
elimination half-life of only 4–5 d [35]. In addition, the magnitude
of piperaquine dosing is limited by gastrointestinal side effects
including nausea [13]. Currently recommended doses of dihy-
droartemisinin-piperaquine may be inadequate in young children
[36] such as those who participated in our present and previous [5]
studies, but higher doses may have reduced tolerability. Gastro-
intestinal and other symptoms in our artemisinin-naphthoquine-
treated children were mild and short-lived despite the use of the
manufacturer’s recommended single-dose regimen on three
consecutive days.
There are theoretical reasons why artemisinin-naphthoquine
may be a suboptimal ACT. As shown by ourselves [10] and others
[37], auto-induction of artemisinin metabolism results in declining
plasma concentrations over the 3 d of treatment. Artemether also
induces its own metabolism [38], but unlike artemisinin, which has
an inactive metabolite, artemether is converted to dihydroartemi-
sinin, which has the greatest activity of all derivatives against P.
falciparum [39]. These pharmacokinetic/pharmacodynamic fac-
tors reflect the relatively low efficacy of artemisinin-naphthoquine
given for less than 3 d [8,9,11] and may have contributed to the
greater percentage of gametocytemic children during the first 2 wk
after artemisinin-naphthoquine treatment in the present study.
The persistence of P. falciparum gametocytemia has implications
for malaria control and could be managed by administration of
single-dose primaquine, provided that cost-effective point-of-care
screening for glucose-6-phosphate dehydrogenase deficiency is
available [40]. It is possible that the need for longer courses of
primaquine for radical cure of P. vivax may be less with
artemisinin-naphthoquine given the lack of appearance of asexual
forms of this species during the 42-d follow-up period in children
treated for acute malaria with this ACT, but this possibility needs
to be evaluated in further studies with longer-term follow-up.
Despite potential pharmacokinetic/pharmacodynamic short-
comings, initial asexual parasite clearance was as rapid with
artemisinin-naphthoquine as with artemether-lumefantrine. There
is in vitro evidence of cross-resistance between chloroquine and
naphthoquine in P. falciparum isolates from PNG, as is also the
case for piperaquine [41]. Whether this has clinical implications
for recrudescence in areas of chloroquine-resistant P. falciparum
and P. vivax is uncertain, but it did not appear influential in the
present study, even though the majority of P. falciparum strains in
Madang Province (.80%) show in vitro evidence of chloroquine
resistance with near fixation of the resistance-associated pfcrt allele
Figure 2. Electrocardiographic QTc intervals after treatment for
uncomplicated malaria. Data are median and interquartile range
(vertical bars) for artemether-lumefantrine (m, solid lines) and
artemisinin-naphthoquine (N, dashed lines). **p,0.01 for between-
treatment comparisons.
doi:10.1371/journal.pmed.1001773.g002
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[40]. The three-dose artemisinin-naphthoquine combination
regimen that complied with WHO recommendations for all
ACTs [12] and that was developed for the present study to
maximize efficacy against asexual and sexual parasite forms [11]
could have unmasked significant adverse effects such as the
hepatotoxicity that prevented inclusion of artesunate-pyronaridine
in the present study [16,17,42], but the present safety data are
reassuring.
Naphthoquine is a tetra-aminoquinoline drug, and our previous
preliminary safety study of artemisinin-naphthoquine in older PNG
children did not find evidence of aminoquinoline-specific side effects
such as hearing loss, orthostatic hypotension, and hypoglycemia
[11]. Similarly, the artemisinin-naphthoquine-treated children in
the present study did not complain of deafness, tinnitus, dizziness, or
posture-related symptoms during follow-up, and no cases of
hypoglycemia were recorded. The lack of hematologic and
hepatorenal toxicity in the present study is also consistent with
our previous findings [11]. An important outcome variable in the
present study was electrocardiographic effects, and there was
significant QTc prolongation between baseline and 4 h after the
final dose in our artemisinin-naphthoquine-treated children. Since
there were no significant between-group differences in pulse rate
and fever clearance during initial monitoring, this QTc prolonga-
tion is consistent with a naphthoquine-specific effect rather than
reflecting a disproportionately larger reduction in sympathetic
activity with recovery in artemisinin-naphthoquine-treated children
that could have independently promoted an increase in the QTc
interval in this group [43].
Many aminoquinoline drugs cause QTc prolongation. Chloro-
quine increases the QTc by a mean of up to 30 msec
0.5 in healthy
volunteers [44], but no malignant arrhythmias or sudden deaths
have been reported with recommended antimalarial doses [43].
Piperaquine also has this effect, with studies in children in PNG
and Cambodia showing QTc prolongation similar to that in the
present study for children treated with artemisinin-naphthoquine
[19,20]. Repeated piperaquine dosing with the potential for
accumulation is not associated with definite cardiotoxicity [45],
and there is no in vitro evidence of torsadogenic or other pro-
arrhythmic effects [46]. In the case of halofantrine (now
withdrawn), cardiotoxicity is plasma-concentration-dependent
[43], but the day-2 QTc prolongation observed in our artemisi-
nin-naphthoquine-treated children had resolved by day 7, when
plasma naphthoquine concentrations would still have been high
[10].
This latter observation, amongst other considerations, suggests
that the artemisinin-naphthoquine regimen used in the present
study was not pro-arrhythmic. Relatively frequent QTc prolonga-
tion has been observed in young children presenting with
untreated malaria [43] and other serious illnesses [47], but it is
transient and not associated with adverse outcomes. There has
been a lack of clinically evident cardiotoxicity in the present and
other studies of naphthoquine [8], including three daily doses for
Table 4. Electrocardiographic QTc measurements by allocated treatment.
QTc (msec
0.5) Artemether-Lumefantrine Artemisinin-Naphthoquine p-Value
Day 0 n= 68 n= 80
Median (IQR) 422 (408–443) 422 (411–444) 0.96




Day 2 n= 27 n= 75
Median (IQR) 439 (427–445) 447 (433–472) 0.003




Day 3 n= 62 n= 84
Median (IQR) 444 (430–454) 443 (428–454) 0.82




Day 7 n= 69 n= 85
Median (IQR) 432 (415–444) 425 (414–444) 0.64
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vivax malaria in adults [31]. Nevertheless, given concerns that
piperaquine-containing ACTs should not be used in people who
have, or are at risk of, QTc prolongation or cardiac arrhythmias
(including those with electrolyte disturbance such as hypokalemia
and hypocalcemia), and that they should not be taken with other
drugs that prolong the QTc interval [48], it may be appropriate to
recommend similar restrictions for three-dose artemisinin-
naphthoquine regimens.
Table 5. Baseline characteristics of patients classified by Plasmodium species and allocated treatment.













Male sex (percent) 50.0% 57.1% 0.32 40.0% 40.7% .0.99
Age (months) 43.4615.6 44.8615.7 0.54 37.1615.2 36.0613.9 0.81
Weight (kg) 12.662.4 12.862.6 0.58 12.262.2 11.962.2 0.63
Mid-upper-arm circumference
(cm)
14.461.1 14.561.3 0.62 14.160.9 14.460.9 0.26
Body mass index (kg/m2) 14.461.7 14.762.0 0.38 14.561.3 14.861.8 0.56
Heart rate (/min) 123621 125622 0.50 121624 120618 0.93
Respiratory rate (/min) 3268 3269 0.86 34611 33613 0.79
Axillary temperature (6C) 38.261.3 38.261.4 0.82 38.261.5 37.961.7 0.52
Enlarged spleen (percent) 49.4% 53.4% 0.65 52.9% 33.3% 0.34
Parasite density (/ml whole blood) 23,277 (9,447–45,613) 24,976 (13,674–51,867) 0.33 6,146 (1,545–18,893) 7,252 (1,372–15,724) 0.86
Hemoglobin (g/l) 92.0617.0 90.9616.9 0.66 92.6617.9 98.0616.3 0.29
Blood glucose (mmol/l) 6.962.1 6.761.9 0.46 6.262.4 7.161.8 0.21
Total drug dose over 3 d (mg/kg)
Artemether 12.0 [8.6–20.0] 11.2 [8.6–16.0]
Lumefantrine 72.0 [51.4–120.0] 67.4 [51.4–96.0]
Artemisinin 62.5 [37.5–75.0] 68.2 [48.7–75.0]
Naphthoquine 25.0 [15–30.0] 27.3 [19.5–30.0]
Data are percentage, mean 6 standard deviation, median (interquartile range), or median [absolute range].
doi:10.1371/journal.pmed.1001773.t005
Table 6. Fever and parasite clearance times by Plasmodium species and allocated treatment.












(n = 27) p-Value
Fever clearance (percent)
Day 1 88/100 (88.0%) 88/98 (89.8%) 0.82 17/20 (85.0%) 26/27 (96.3%) 0.30
Day 2 95/98 (96.9%) 93/98 (94.9%) 0.72 17/19 (89.5%) 26/27 (96.3%) 0.56
Day 3 99/99 (100%) 96/98 (98.0%) 0.25 19/19 (100%) 26/26 (100%) —
Day 7 93/99 (93.9%) 94/98 (95.9%) 0.75 20/20 (100%) 24/26 (92.3%) 0.50
Mean (95% CI) FCT (days) 1.2 (1.1–1.3) 1.1 (1.0–1.2) 0.28 1.4 (1.0–1.8) 1.1 (0.9–1.4) 0.50
Parasite clearance (percent)
Day 1 33/99 (33.3%) 30/98 (30.6%) 0.76 16/19 (84.2%) 23/27 (85.2%) .0.99
Day 2 88/99 (88.9%) 86/98 (87.8%) 0.83 20/20 (100%) 27/27 (100%) —
Day 3 97/98 (99.0%) 96/98 (98.0%) .0.99 20/20 (100%) 27/27 (100%) —
Day 7 98/98 (100%) 98/98 (100%) — 20/20 (100%) 27/27 (100%) —
Mean (95% CI) PCT (days) 1.8 (1.7–1.9) 1.8 (1.7–1.9) 0.66 1.2 (1.0–1.3) 1.1 (1.0–1.3) 0.99
Data are number/total (percentage) or mean (95% confidence interval).
doi:10.1371/journal.pmed.1001773.t006
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Our study had limitations. Baseline microscopy by study staff
under field conditions led to 11% of the 267 randomized patients
being included when they had sub-threshold parasitemia based on
expert microscopy, while electrocardiography proved difficult in a
significant minority of children. We did not directly observe all
artemether-lumefantrine doses, but parents/guardians were in-
structed as to the importance of all doses given at home, adherence
was assessed at the next follow-up visit, and day-7 plasma
lumefantrine concentrations were consistent with full adherence
in each case. The children screened and recruited were drawn
from coastal PNG communities that are typical of those in
Oceania where hyper- or holo-endemic transmission of multiple
Plasmodium species is found. It is possible that treatment responses
in children with uncomplicated malaria who have been raised in
Figure 3. Kaplan-Meier plots showing percentages of patients positive for PCR-corrected P. falciparum and for PCR-uncorrected P.
vivax after treatment. Data are for artemether-lumefantrine (solid lines) and artemisinin-naphthoquine (dashed lines). Numbers of children at risk
at each time point are shown for artemether-lumefantrine (AL) and artemisinin-naphthoquine (AN). p-Values are for log-rank tests.
doi:10.1371/journal.pmed.1001773.g003
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P. falciparum, day 28 n 190 94 96
ACPR n 189 93 96
Percent (95% CI) 99.5 (96.7–100) 98.9 (93.4–100) 100 (95.2–100) 1.1 (23.8 to 6.6) 0.50 (one-sided)
ETF/LCF/LPF (percent) 0/0/0.5 0/0/1.1 0/0/0
P. falciparum, day 42 n 186 92 94
ACPR n 184 90 94
Percent (95% CI) 98.9 (95.8–99.8) 97.8 (91.6–99.6) 100 (95.1–100) 2.2 (23.0 to 8.4) 0.24 (one-sided)
ETF/LCF/LPF (percent) 0/0.5/0.5 0/1.1/1.1 0/0/0
P. vivax, day 28 n 46 20 26
ACPR n 39 13 26
Percent (95% CI) 84.8 (70.5–93.2) 65.0 (41.0–83.7) 100 (84.0–100) 35.0 (10.7 to 59.1) 0.001 (two-sided)
ETF/LCF/LPF (percent) 0/0/15.2 0/0/35.0 0/0/0
P. vivax, day 42 n 46 20 26
ACPR n 32 6 26
Percent (95% CI) 69.6 (54.1–81.8) 30.0 (12.8–54.3) 100 (84.5–100) 70.0 (40.9 to 87.2) ,0.001 (two-sided)
ETF/LCF/LPF (percent) 0/2.2/28.3 0/5.0/65.0 0/0/0
P. vivax after treatment
for falciparum malaria,
day 42
n 188 94 94
ACPR n 156 62 94
Percent (95% CI) 83.0 (76.7–87.9) 66.0 (55.4–75.2) 100 (95.1–100) 34.0 (23.6 to 44.6) ,0.001 (one-sided)
ETF/LCF/LPF (percent) 0/0/17.0 0/0/34.0 0/0/0
doi:10.1371/journal.pmed.1001773.t007
Table 8. Per-protocol secondary endpoint analysis of response in children with PCR-uncorrected P. falciparum reinfections or PCR-







Naphthoquine Difference (95% CI) p-Value
P. falciparum, day 28 n 190 94 96
ACPR n 188 92 96
Percent (95% CI) 98.9 (95.9–99.8) 97.9 (91.8–99.6) 100 (95.2–100) 2.1 (–3.0 to 8.2) 0.24
ETF/LCF/LPF (percent) 0/0.5/0.5 0/1.1/1.1 0/0/0
P. falciparum, day 42 n 186 92 94
ACPR n 181 87 94
Percent (95% CI) 97.3 (93.5– 99.0) 94.6 (87.2–98.0) 100 (95.1–100) 5.4 (20.5 to 12.8) 0.028
ETF/LCF/LPF (percent) 0/0.5/2.2 0/1.1/4.3 0/0/0
P. vivax, day 28 n 46 20 26
ACPR n 42 16 26
Percent (95% CI) 91.3 (78.3–97.2) 80.0 (55.7–93.4) 100 (84.0–100) 20.0 (20.9 to 44.3) 0.030
ETF/LCF/LPF (percent) 0/2.2/6.5 0/5.0/15.0 0/0/0
P. vivax, day 42 n 46 20 26
ACPR n 38 12 26
Percent (95% CI) 82.6 (68.1–91.7) 60.0 (36.4–80.0) 100 (84.0–100) 40.0 (14.4 to 63.6) ,0.001
ETF/LCF/LPF (percent) 0/2.2/15.2 0/5.0/35.0 0/0/0
doi:10.1371/journal.pmed.1001773.t008
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areas with lower-level transmission may be attenuated because of
their reduced or absent malarial immunity. Nevertheless, ACTs
such as artemether-lumefantrine are considered efficacious where
there is unstable transmission [12], while most of the studies
evaluating artemisinin-naphthoquine—which had mostly accept-
able efficacy—were conducted in this epidemiologic setting [8,9].
The strengths of the study are the high rates of laboratory
(including parasitologic) data collection and the $92% retention
rate of children in each of the four species/treatment arms, which
was greater than anticipated when sample sizes were determined
and greater than in our previous multi-arm trial in PNG children
(with, for example, only 77% in one of the arms [5]).
Table 9. Modified intention-to-treat analysis of treatment response by treatment allocation utilizing a worst-case scenario (i.e., all
instances of missing data during follow-up scored as treatment failure).







P. falciparum, day 28 n 198 100 98
ACPR n 189 93 96
Percent (95% CI) 95.5 (91.3–97.8) 93.0 (85.6–96.9) 98.0 (92.1–99.7) 5.0 (22.1 to 12.5) 0.09 (one-sided)
P. falciparum, day 42 n 198 100 98
ACPR n 184 90 94
Percent (95% CI) 92.9 (88.2–95.9) 90.0 (82.0–94.8) 95.9 (89.3–98.7) 5.9 (22.3 to 14.4) 0.09 (one-sided)
P. vivax, day 28 N 47 20 27
ACPR n 39 13 26
Percent (95% CI) 83.0 (68.7–91.9) 65.0 (41.0–83.7) 96.3 (79.1–99.8) 31.3 (5.9 to 55.6) 0.007 (two-sided)
P. vivax, day 42 N 47 20 27
ACPR n 32 6 26
Percent (95% CI) 68.1 (52.8–80.5) 30.0 (12.8–54.3) 96.3 (79.1–99.8) 66.3 (36.5 to 83.8) ,0.001 (two-sided)
P. vivax after treatment
for falciparum malaria,
day 42
N 198 100 98
ACPR n 156 62 94
Percent (95% CI) 78.8 (72.3–84.1) 62.0 (51.7–71.4) 95.9 (89.3–98.7) 33.9 (22.5 to 44.6) ,0.001 (one-sided)
doi:10.1371/journal.pmed.1001773.t009
Table 10. Modified intention-to-treat analysis of treatment response by treatment allocation utilizing a best-case scenario (i.e., all
instances of missing data during follow-up scored as parasite-negative).







P. falciparum, day 28 n 198 100 98
ACPR n 197 99 98
Percent (95% CI) 99.5 (96.8–100) 99.0 (93.8–100) 100 (95.3–100) 1.0 (23.8 to 6.2) 0.51 (one-sided)
P. falciparum, day 42 n 198 100 98
ACPR n 196 98 98
Percent (95% CI) 99.0 (96.0–99.8) 98.0 (92.3–99.7) 100 (95.3–100) 2.0 (23.0 to 7.7) 0.25 (one-sided)
P. vivax, day 28 n 47 20 27
ACPR n 40 13 27
Percent (95% CI) 84.8 (70.5–93.2) 65.0 (41.0–83.7) 100 (84.5–100) 35.0 (10.7 to 59.1) 0.001 (two-sided)
P. vivax, day 42 n 47 20 27
ACPR n 33 6 27
Percent (95% CI) 69.6 (54.1–81.8) 30.0 (12.8–54.3) 100 (84.5–100) 70.0 (41.2 to 87.2) ,0.001 (two-sided)
P. vivax after treatment
for falciparum malaria,
day 42
n 198 100 98
ACPR n 166 68 98
Percent (95% CI) 83.8 (77.8–88.5) 68.0 (57.8–76.8) 100 (95.3–100) 32.0 (22.0 to 42.2) ,0.001 (one-sided)
doi:10.1371/journal.pmed.1001773.t010
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Figure 4. Proportions of patients with gametocytes during follow-up after treatment for P. falciparum and for P. vivax. Data are for
artemether-lumefantrine (m, solid lines) and artemisinin-naphthoquine (N, dashed lines). *p,0.05, **p,0.01 for between-treatment comparisons.
doi:10.1371/journal.pmed.1001773.g004
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Figure 5. Hemoglobin concentrations during follow-up after treatment for P. falciparum and for P. vivax. Data are mean and standard
deviation (vertical bars) for artemether-lumefantrine (m, solid lines) and artemisinin-naphthoquine (N, dashed lines). **p,0.01 for between-
treatment comparisons.
doi:10.1371/journal.pmed.1001773.g005
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The efficacy, tolerability, and safety of three daily doses of
artemisinin-naphthoquine suggest that this regimen should be
considered together with other currently available effective ACTs
for treatment of uncomplicated malaria in PNG and similar
epidemiologic settings with transmission of multiple Plasmodium
species. Artemisinin-naphthoquine may have advantages where P.
vivax predominates. Although pharmaco-economic analyses were
beyond the scope of the present study, it seems likely that the
additional cost of three doses compared to the single dose currently
recommended will be more than offset by the substantial reduction
in post-treatment vivax malaria.
Supporting Information
Text S1 Consort checklist for a randomized clinical
trial of artemisinin-naphthoquine versus artemether-
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nin-based combination therapies for Papuan New




We gratefully acknowledge the support of patients and their families, staff
at the Mugil and Alexishafen Health Centers, and staff in the Vector Borne
Diseases Unit of the PNG Institute of Medical Research.
Author Contributions
Conceived and designed the experiments: TMED. Performed the
experiments: ML BRM JMB GY CB JW JHK TK LM BK LJR NS LL
SK AR-U. Analyzed the data: WAD ML BRM TMED. Wrote the first
draft of the manuscript: ML BRM. Wrote the paper: ML BRM JMB GY
CB JW JHK TK LM BK LJR NS LL SK WAD AR-U IM PMS IB
TMED. Agree with manuscript results and conclusions: ML BRM JMB
GY CB JW JHK TK LM BK LJR NS LL SK WAD AR-U IM PMS IB
TMED. Enrolled patients: ML BRM JMB GY CB JW. All authors have
read, and confirm that they meet, ICMJE criteria for authorship.
References
1. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, et al. (2012) Global
malariamortality between 1980 and 2010: a systematic analysis. Lancet 379: 413–431.
2. Mendis K, Sina BJ, Marchesini P, Carter R (2001) The neglected burden of
Plasmodium vivax malaria. Am J Trop Med Hyg 64: 97–106.
3. Baird JK (2008) Real-world therapies and the problem of vivax malaria.
N Engl J Med 359: 2601–2603.
4. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, et al. (2007) Vivax malaria:
neglected and not benign. Am J Trop Med Hyg 77: 79–87.
5. Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, et al. (2008) A trial of
combination antimalarial therapies in children from Papua New Guinea.
N Engl J Med 359: 2545–2557.
6. Papua New Guinea National Department of Health (2009) National malaria
treatment protocol. Port Moresby: National Department of Health.
7. Manning L, Laman M, Law I, Bona C, Aipit S, et al. (2011) Features and
prognosis of severe malaria caused by Plasmodium falciparum, Plasmodium
vivax and mixed Plasmodium species in Papua New Guinean children. PLoS
ONE 6: e29203.
8. Wang JY, Cao WC, Shan CQ, Zhang M, Li GF, et al. (2004) Naphthoquine
phosphate and its combination with artemisinine. Acta Trop 89: 375–381.
9. Hombhanje FW, Huang Q (2010) Artemisinin-naphthoquine combination
(ARCOH): an overview of the progress. Pharmaceuticals 3: 3581–3593.
10. Batty KT, Salman S, Moore BR, Benjamin J, Lee ST, et al. (2012) Artemisinin-
naphthoquine combination therapy for uncomplicated pediatric malaria: a
pharmacokinetic study. Antimicrob Agents Chemother 56: 2472–2484.
11. Benjamin J, Moore B, Lee ST, Senn M, Griffin S, et al. (2012) Artemisinin-
naphthoquine combination therapy for uncomplicated pediatricmalaria: a tolerability,
safety, and preliminary efficacy study. Antimicrob Agents Chemother 56: 2465–2471.
12. World Health Organization (2010) Guidelines for the treatment of malaria, 2nd
edition. Geneva: World Health Organization
13. Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF (2005) Piperaquine: a
resurgent antimalarial drug. Drugs 65: 75–87.
14. Barnadas C, Koepfli C, Karunajeewa HA, Siba PM, Davis TM, et al. (2011)
Characterization of treatment failure in efficacy trials of drugs against
Plasmodium vivax by genotyping neutral and drug resistance-associated
markers. Antimicrob Agents Chemother 55: 4479–4481.
15. World Health Organization (2003) Assessment and monitoring of antimalarial
drug efficacy for the treatment of uncomplicated falciparum malaria. Geneva:
World Health Organization.
16. Bukirwa H, Unnikrishnan B, Kramer CV, Sinclair D, Nair S, et al. (2014)
Artesunate plus pyronaridine for treating uncomplicated Plasmodium falci-
parum malaria. Cochrane Database Syst Rev 3: CD006404.
17. European Medicines Agency (2012) Assessment report. Pyramax—pyronaridine
tetraphosphate/artesunate. Procedure No.: EMEA/H/W/002319. Available:
http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/06/
WC500129290.pdf. Accessed 19 November 2014.
18. World Health Organization (2000) Severe falciparum malaria. World Health
Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg 94
(Suppl 1): S1–S90.
19. Karunajeewa H, Lim C, Hung TY, Ilett KF, Denis MB, et al. (2004) Safety
evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in
Cambodian children and adults with malaria. Br J Clin Pharmacol 57: 93–99.
20. Moore BR, Benjamin JM, Salman S, Griffin S, Ginny E, et al. (2014) Effect of
co-administered fat on the tolerability, safety and pharmacokinetic properties of
dihydroartemisinin-piperaquine in Papua New Guinean children with uncom-
plicated malaria. Antimicrob Agents Chemother 58: 5784–5794.
21. Ashley EA, Stepniewska K, Lindegardh N, Annerberg A, Kham A, et al. (2007)
How much fat is necessary to optimize lumefantrine oral bioavailability? Trop
Med Int Health 12: 195–200.
22. Cattamanchi A, Kyabayinze D, Hubbard A, Rosenthal PJ, Dorsey G (2003)
Distinguishing recrudescence from reinfection in a longitudinal antimalarial
drug efficacy study: comparison of results based on genotyping of MSP-1, MSP-
2, and GLURP. Am J Trop Med Hyg 68: 133–139.
23. Felger I, Beck HP (2002) Genotyping of Plasmodium falciparum. PCR-RFLP
analysis. Methods Mol Med 72: 117–129.
24. Wong RP, Salman S, Ilett KF, Siba PM, Mueller I, et al. (2011) Desbutyl-
lumefantrine is a metabolite of lumefantrine with potent in vitro antimalarial
activity that may influence artemether-lumefantrine treatment outcome.
Antimicrob Agents Chemother 55: 1194–1198.
25. Salman S, Page-Sharp M, Griffin S, Kose K, Siba PM, et al. (2011) Population
pharmacokinetics of artemether, lumefantrine, and their respective metabolites
in Papua New Guinean children with uncomplicated malaria. Antimicrob
Agents Chemother 55: 5306–5313.
26. Manning L, Laman M, Townsend MA, Chubb SP, Siba PM, et al. (2011)
Reference intervals for common laboratory tests in Melanesian children.
Am J Trop Med Hyg 85: 50–54.
27. Blackwelder WC (1982) ‘‘Proving the null hypothesis’’ in clinical trials. Control
Clin Trials 3: 345–353.
28. Pocock SJ (1983) Clinical trials: a practical approach. Chichester: John Wiley.
29. Krudsood S, Chalermrut K, Pengruksa C, Srivilairit S, Silachamroon U, et al.
(2003) Comparative clinical trial of two-fixed combinations dihydroartemisinin-
napthoquine-trimethoprim (DNP) and artemether-lumefantrine (Coartem/
Riamet) in the treatment of acute uncomplicated falciparum malaria in
Thailand. Southeast Asian J Trop Med Public Health 34: 316–321.
30. Tjitra E, Hasugian AR, Siswantoro H, Prasetyorini B, Ekowatiningsih R, et al.
(2012) Efficacy and safety of artemisinin-naphthoquine versus dihydroartemisi-
nin-piperaquine in adult patients with uncomplicated malaria: a multi-centre
study in Indonesia. Malar J 11: 153.
31. Liu H, Yang HL, Xu JW, Wang JZ, Nie RH, et al. (2013) Artemisinin-
naphthoquine combination versus chloroquine-primaquine to treat vivax
malaria: an open-label randomized and non-inferiority trial in Yunnan Province,
China. Malar J 12: 409.
32. Hung TY, Davis TM, Ilett KF, Karunajeewa H, Hewitt S, et al. (2004)
Population pharmacokinetics of piperaquine in adults and children with
uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol 57: 253–
262.
33. Karunajeewa HA, Ilett KF, Mueller I, Siba P, Law I, et al. (2008)
Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian
children with uncomplicated malaria. Antimicrob Agents Chemother 52: 237–
243.
34. Salman S, Page-Sharp M, Batty KT, Kose K, Griffin S, et al. (2012)
Pharmacokinetic comparison of two piperaquine-containing artemisinin combi-
nation therapies in Papua New Guinean children with uncomplicated malaria.
Antimicrob Agents Chemother 56: 3288–3297.
35. Ezzet F, Mull R, Karbwang J (1998) Population pharmacokinetics and
therapeutic response of CGP 56697 (artemether + benflumetol) in malaria
patients. Br J Clin Pharmacol 46: 553–561.
Artemisinin-Naphthoquine for Pediatric Malaria
PLOS Medicine | www.plosmedicine.org 16 December 2014 | Volume 11 | Issue 12 | e1001773
36. WorldWide Antimalarial Resistance Network (WWARN) DP Study Group
(2013) The effect of dosing regimens on the antimalarial efficacy of
dihydroartemisinin-piperaquine: a pooled analysis of individual patient data.
PLoS Med 10: e1001564.
37. Hassan Alin M, Ashton M, Kihamia CM, Mtey GJ, Bjorkman A (1996) Multiple
dose pharmacokinetics of oral artemisinin and comparison of its efficacy with
that of oral artesunate in falciparum malaria patients. Trans R Soc Trop Med
Hyg 90: 61–65.
38. van Agtmael MA, Cheng-Qi S, Qing JX, Mull R, van Boxtel CJ (1999) Multiple
dose pharmacokinetics of artemether in Chinese patients with uncomplicated
falciparum malaria. Int J Antimicrob Agents 12: 151–158.
39. Skinner TS, Manning LS, Johnston WA, Davis TM (1996) In vitro stage-specific
sensitivity of Plasmodium falciparum to quinine and artemisinin drugs.
Int J Parasitol 26: 519–525.
40. Moore BR, Salman S, Benjamin J, Page-Sharp M, Robinson LJ, et al. (2014)
Pharmacokinetic properties of single-dose primaquine in Papua New Guinean
children: feasibility of abbreviated high-dose regimens for radical cure of vivax
malaria. Antimicrob Agents Chemother 58: 432–439.
41. Wong RP, Lautu D, Tavul L, Hackett SL, Siba P, et al. (2010) In vitro sensitivity
of Plasmodium falciparum to conventional and novel antimalarial drugs in
Papua New Guinea. Trop Med Int Health 15: 342–349.
42. Kurth F, Belard S, Basra A, Ramharter M (2011) Pyronaridine-artesunate
combination therapy for the treatment of malaria. Curr Opin Infect Dis 24:
564–569.
43. White NJ (2007) Cardiotoxicity of antimalarial drugs. Lancet Infect Dis 7: 549–
558.
44. Bustos MD, Gay F, Diquet B, Thomare P, Warot D (1994) The pharmaco-
kinetics and electrocardiographic effects of chloroquine in healthy subjects. Trop
Med Parasitol 45: 83–86.
45. Lwin KM, Phyo AP, Tarning J, Hanpithakpong W, Ashley EA, et al. (2012)
Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly
dihydroartemisinin-piperaquine chemoprevention in adults at high risk of
malaria. Antimicrob Agents Chemother 56: 1571–1577.
46. Borsini F, Crumb W, Pace S, Ubben D, Wible B, et al. (2012) In vitro
cardiovascular effects of dihydroartemisin-piperaquine combination compared
with other antimalarials. Antimicrob Agents Chemother 56: 3261–3270.
47. Van Dorn CS, Johnson JN, Taggart NW, Thorkelson L, Ackerman MJ (2011)
QTc values among children and adolescents presenting to the emergency
department. Pediatrics 128: e1395–1401.




Artemisinin-Naphthoquine for Pediatric Malaria
PLOS Medicine | www.plosmedicine.org 17 December 2014 | Volume 11 | Issue 12 | e1001773
Editors’ Summary
Background. Malaria is a mosquito-borne parasitic disease
that kills more than 600,000 people (mainly young children
in sub-Saharan Africa) every year. Plasmodium falciparum
causes most of these deaths, but P. vivax is the most
common and most widely distributed cause of malaria
outside sub-Saharan Africa. Infection with malaria parasites
causes recurring flu-like symptoms and must be treated
promptly with antimalarial drugs to prevent the develop-
ment of anemia and potentially fatal damage to the brain
and other organs. In the past, malaria was treated with
‘‘monotherapies’’ such as chloroquine, but the parasites
quickly developed resistance to many of these inexpensive
drugs. The World Health Organization now recommends
artemisinin combination therapy (ACT) for first-line treat-
ment of malaria in all regions where there is drug-resistant
malaria. In ACT, artemisinin derivatives (fast-acting antima-
larial drugs that are rapidly cleared from the body) are used
in combination with a slower acting, more slowly eliminated
partner drug to prevent reemergence of the original
infection and to reduce the chances of the malaria parasites
becoming resistant to either drug.
Why Was This Study Done? Because falciparum and vivax
malaria respond differently to antimalarial drugs, wherever
there is transmission of both types of malaria but limited
facilities for species-specific malaria diagnosis—as in Papua
New Guinea—compromises have to be made about which
ACT should be used for the treatment of malaria. Thus,
Papua New Guinea’s national guidelines recommend arte-
mether-lumefantrine, which is effective against the more
deadly P. falciparum, for first-line treatment of uncomplicat-
ed (mild) malaria even though this ACT is ineffective against
the more common P. vivax. In this open-label randomized
trial (a study in which participants are randomly assigned to
receive different drugs but know which drug they are being
given), the researchers ask whether an alternative ACT might
be preferable for the treatment of uncomplicated malaria in
young children in Papua New Guinea by comparing
outcomes after treatment with artemether-lumefantrine
versus artemisinin-naphthoquine (an ACT that should be
more effective against vivax malaria than artemether-
lumefantrine because naphthoquine stays in the body
longer than lumefantrine). Specifically, the researchers test
the non-inferiority of artemisinin-naphthoquine compared to
artemether-lumefantrine for the treatment of falciparum
malaria (whether artemisinin-naphthoquine is not worse
than artemether-lumefantrine) and the superiority of arte-
misinin-naphthoquine compared to artemether-lumefantrine
for the treatment of vivax malaria (whether artemisinin-
naphthoquine is better than artemether-lumefantrine).
What Did the Researchers Do and Find? The researchers
assigned nearly 250 children (aged 0.5 to 5 years) with
falciparum malaria, vivax malaria, or both types of malaria to
receive six doses of artemether-lumefantrine over three days
or three daily doses of artemisinin-naphthoquine. They then
followed the children to see how many children in each
treatment group and with each type of malaria were free of
malaria 42 days after treatment (an ‘‘adequate clinical and
parasitological response’’). Among the patients originally
infected with P. falciparum, 97.8% of those treated with
artemether-lumefantrine and 100% of those treated with
artemisinin-naphthoquine were clear of their original P.
falciparum infection (though some had acquired a new P.
falciparum infection) 42 days after treatment. By contrast,
among the patients infected with P. vivax, 30% of those
treated with artemether-lumefantrine and 100% of those
treated with artemisinin-naphthoquine were clear of P. vivax
infection 42 days after treatment. Both ACTs were safe and
well tolerated.
What Do These Findings Mean? These findings indicate
that artemisinin-naphthoquine was non-inferior to arte-
mether-lumefantrine for the treatment of uncomplicated
falciparum malaria among young children in Papua New
Guinea and had greater efficacy than artemether-lumefan-
trine against vivax malaria. The accuracy of these findings
may be limited by several aspects of the study design. For
example, not all the artemether-lumefantrine doses were
directly observed, so some children may not have received
the full treatment course. Moreover, because all the study
participants lived in coastal communities in Papua New
Guinea where malaria is highly endemic, treatment respons-
es among children living in areas with lower levels of malaria
transmission might be different. Nevertheless, these findings
suggest that artemisinin-naphthoquine should be consid-
ered alongside other ACTs for the treatment of uncompli-
cated malaria in regions where there is transmission of
multiple Plasmodium species and that artemisinin-naphtho-
quine may be better than artemether-lumefantrine for the
treatment of uncomplicated malaria in young children in
regions where P. vivax predominates.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001773.
N Information is available from the World Health Organiza-
tion on malaria (in several languages); the World Malaria
Report 2013 provides details on the current global malaria
situation, including information on malaria in Papua New
Guinea; the World Health Organization’s Guidelines for the
Treatment of Malaria is available
N The US Centers for Disease Control and Prevention
provides information on malaria (in English and Spanish),
including personal stories about malaria
N Information is available from the Roll Back Malaria
Partnership on the global control of malaria, including
information about malaria in Papua New Guinea, malaria in
children, and ACTs
N The Malaria Vaccine Initiative has a fact sheet on
Plasmodium vivax malaria
N MedlinePlus provides links to additional information on
malaria (in English and Spanish)
N More information about this trial is available
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